Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in-home skilled nursing services to medically complex children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and non-clinical care, including support services and personal care services; and in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.4B | $269M | $225M | $118M | 115.3% | 20.2% | -2159.1% |
| 2024 | $2.0B | $187M | $-11M | $26M | 9.0% | 6.8% | -91.9% |
| 2023 | $1.9B | $39M | $-135M | $14M | 105.6% | 6.0% | -79.7% |
| 2022 | $1.8B | $-525M | $-662M | $-60M | 15857.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 2,433.20 |
| Operating Revenue | 2,433.20 |
| Cost Of Revenue | 1,622.72 |
| Gross Profit | 810.48 |
| Operating Expense | 550.21 |
| Selling General And Administration | 528.80 |
| Total Expenses | 2,172.92 |
| Operating Income | 260.28 |
| Total Operating Income As Reported | 256.46 |
| EBITDA | 269.40 |
| Normalized EBITDA | 285.52 |
| EBIT | 241.18 |
| Interest Income | 2.83 |
| Interest Expense | 134.23 |
| Net Interest Income | -137.26 |
| Other Non Operating Income Expenses | 0.05 |
| Other Income Expense | -16.07 |
| Interest Income Non Operating | 2.83 |
| Interest Expense Non Operating | 134.23 |
| Net Non Operating Interest Income Expense | -137.26 |
| Pretax Income | 106.95 |
| Tax Provision | -118.09 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -6.45 |
| Net Income Continuous Operations | 225.03 |
| Net Income From Continuing And Discontinued Operation | 225.03 |
| Net Income From Continuing Operation Net Minority Interest | 225.03 |
| Net Income | 225.03 |
| Net Income Common Stockholders | 225.03 |
| Net Income Including Noncontrolling Interests | 225.03 |
| Normalized Income | 234.71 |
| Diluted NI Availto Com Stockholders | 225.03 |
| Basic Average Shares | - |
| Diluted Average Shares | - |
| Reconciled Depreciation | 28.22 |
| Reconciled Cost Of Revenue | 1,605.03 |
| Total Unusual Items | -16.12 |
| Total Unusual Items Excluding Goodwill | -16.12 |
| Special Income Charges | -9.68 |
| Other Special Charges | 5.86 |
| Impairment Of Capital Assets | - |
| Restructuring And Mergern Acquisition | 3.81 |
| Gain On Sale Of Security | -6.44 |
| Depreciation Amortization Depletion Income Statement | 10.54 |
| Depreciation And Amortization In Income Statement | 10.54 |
| General And Administrative Expense | 528.80 |
| Other Gand A | 420.26 |
| Salaries And Wages | 95.03 |
| Rent Expense Supplemental | 13.51 |
| Total Other Finance Cost | 5.85 |
| Other Operating Expenses | 10.86 |
| Rent And Landing Fees | 13.51 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aveanna Healthcare Holdings Inc.this co. | AVAH | $1.4B | 6.42 | 7.40 | 115.3% | 10.26 |
| STAAR Surgical Company | STAA | $1.5B | -18.48 | 4.32 | -23.4% | -36.86 |
| Perrigo Company plc | PRGO | $1.5B | -1.04 | 0.50 | -48.6% | -5.75 |
| NeoGenomics, Inc. | NEO | $1.5B | -13.63 | 1.76 | -12.9% | -44.52 |
| MBX Biosciences, Inc. | MBX |
| 2021 | - | - | - | - | - | - | - |
| $1.5B |
| -16.92 |
| 3.98 |
| -23.6% |
| -14.28 |
| Monte Rosa Therapeutics, Inc. | GLUE | $1.5B | -37.97 | 6.29 | -16.6% | -30.01 |
| Septerna, Inc. | SEPN | $1.4B | -28.93 | 3.70 | -12.8% | -16.63 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | -10.72 | 3.96 | -36.9% | -8.82 |
| Healthcare Services Group, Inc. | HCSG | $1.4B | 23.77 | 2.75 | 11.6% | 14.94 |
| Peer Median | - | -15.27 | 3.83 | -20.0% | -15.45 | |